Earnings Call Summary | PetMed Express(PETS.US) Q4 2024 Earnings Conference
Earnings Call Summary | PetMed Express(PETS.US) Q4 2024 Earnings Conference
The following is a summary of the PetMed Express, Inc. (PETS) Q4 2024 Earnings Call Transcript:
以下是PetMed Express，Inc.(petmed express) Q4 2024業績會議要點:
Financial Performance:
金融業績：
For Q4 2024, PetMed Express reported a revenue of $66.5 million, reflecting a 6.6% increase year-over-year, primarily driven by the acquisition of PetCareRx.
Gross profit margin for the fourth quarter was listed at 27.3%, experiencing a slight decrease from 27.9% in the same quarter last year.
The company reported a net loss of $5 million or $0.25 per diluted share, compared to a net loss of $200,000 or $0.01 per diluted share in the prior year's same quarter.
2024年第四季度，PetMed Express報告了6650萬美元的營業收入，同比增長6.6%，主要由於收購PetCareRx。
第四季度的毛利潤率爲27.3%，略低於去年同期的27.9%。
公司報告淨虧損500萬美元，每股攤薄後爲0.25美元，而去年同期淨虧損200,000美元，每股攤薄後爲0.01美元。
Business Progress:
業務進展：
PetMed Express is focusing on integrating its PetMeds and PetCareRx brands to create a more streamlined operation.
The company is enhancing key relationships with suppliers, improving inventory management, and taking steps to reduce operational costs through consolidation and enhanced technology use.
The company appointed new members to key roles including Chief Marketing Officer and Chief Digital and Technology Officer to drive forward technological improvements and marketing strategies.
PetMed Express專注於整合其PetMeds和PetCareRx品牌，以創建更加高效的控件。
公司正在加強與供應商的關係，改善庫存管理，並採取措施通過整合和增強技術使用來降低運營成本。
公司任命了新的成員擔任關鍵角色，包括首席營銷官和首席數字與技術官，推動技術改進和市場營銷策略。
Opportunities:
機會：
The continued growth in the pet care sector, particularly in medication, food, and health services, presents significant opportunities for PetMed Express.
PetMed Express is expanding its digital capabilities and automation to enhance efficiencies and customer interactions.
寵物保健行業的持續增長，特別是在藥品、食品和健康服務方面，爲PetMed Express帶來了重大機遇。
PetMed Express正在擴展其數字能力和自動化以增強效率和客戶互動。
Risks:
風險：
There was no explicit mention of specific risks facing the company in the forward-looking statements.
前瞻性陳述中並未明確提到公司面臨的特定風險。
More details: PetMed Express IR
更多詳情：PetMed Express IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。